The association between the level of specific IgE to molecular componentsof mites and the expression of CD23 molecule on B lymphocytes in atopic dermatitis patients treated or not treated with dupilumab - Pilot study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F23%3A10466180" target="_blank" >RIV/00179906:_____/23:10466180 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/23:10466180

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=mSQ9EW1Cwp" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=mSQ9EW1Cwp</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/clt2.12278" target="_blank" >10.1002/clt2.12278</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The association between the level of specific IgE to molecular componentsof mites and the expression of CD23 molecule on B lymphocytes in atopic dermatitis patients treated or not treated with dupilumab - Pilot study

Popis výsledku v původním jazyce

Backround: The CD23 molecule has effect on the regulation of IgE sythesis, whwthwr the expression of CD23 ob B lymphocytes is realated to the level of allergenspecific IgE antibodies in patients with atopic dermatitis.Aim: The main of this pilot study was to evaluate the association between the expression of CD23 molecule on B cells and on their subsets (memory, naive, switched, nonswitched, and total B lymphocytes) and the level of specific IgE to molecular components of mites in atopic dermatitis patients (with and without dupilumab therapy).Methods: Forty-five patients suffering from atopic dermatitis were included: 32 patients without dupilumab treatment (10 men, 22 women, average age 35 years), 13 patients with dupilumab treatment (7 men, 6 women, average age 43,4 years) and 30 subjekts as a control group (10 men, 22 , average women, averge age 44,7 years). The serum level of the specific IgE was measured using the components resolved diagnostic microarray-based specific IgE detection assay ALEX2 Allergy Xplorer. In all included patients, the expression of CD23 molecule on B lymphocytes was evaluated with flow cytometry using monoclonal antibodies. For the statistical analysis of the association between expression of CD23 molecule on B lymphocytes and the level of specific IgE to molecular components of mites, we used non-paramertic Krusal-Wallis one-factor analysis of variace with post-hoc by Dunnś&apos;s test with Bonferroni modification and the Spear-man&apos;s rank correlation coefficient; for coefficients higher than 0,41, we report R2 (%, percent of Variation Explained).Results: The association between the expression of CD23 molecule on B cells and the level of specific IgE to molecular components of mites was confirmed only in patients with dupilumab therapy. In these patiens, the highest association was confirmed between the level of specific IgE to Der p 20 and expression of CD23 on switched B lymphocytes (in 48,9 %). In patients without dupilumab, the association between the level of specific IgE to molecular components of mites and the expression of CD23 on B cells and on their subsets is low.Conclusion: Further research is needed to fully understand the underlying mechanism of this phenomenon and its implications for the treatment of atopic dermatitis.

Název v anglickém jazyce

The association between the level of specific IgE to molecular componentsof mites and the expression of CD23 molecule on B lymphocytes in atopic dermatitis patients treated or not treated with dupilumab - Pilot study

Popis výsledku anglicky

Backround: The CD23 molecule has effect on the regulation of IgE sythesis, whwthwr the expression of CD23 ob B lymphocytes is realated to the level of allergenspecific IgE antibodies in patients with atopic dermatitis.Aim: The main of this pilot study was to evaluate the association between the expression of CD23 molecule on B cells and on their subsets (memory, naive, switched, nonswitched, and total B lymphocytes) and the level of specific IgE to molecular components of mites in atopic dermatitis patients (with and without dupilumab therapy).Methods: Forty-five patients suffering from atopic dermatitis were included: 32 patients without dupilumab treatment (10 men, 22 women, average age 35 years), 13 patients with dupilumab treatment (7 men, 6 women, average age 43,4 years) and 30 subjekts as a control group (10 men, 22 , average women, averge age 44,7 years). The serum level of the specific IgE was measured using the components resolved diagnostic microarray-based specific IgE detection assay ALEX2 Allergy Xplorer. In all included patients, the expression of CD23 molecule on B lymphocytes was evaluated with flow cytometry using monoclonal antibodies. For the statistical analysis of the association between expression of CD23 molecule on B lymphocytes and the level of specific IgE to molecular components of mites, we used non-paramertic Krusal-Wallis one-factor analysis of variace with post-hoc by Dunnś&apos;s test with Bonferroni modification and the Spear-man&apos;s rank correlation coefficient; for coefficients higher than 0,41, we report R2 (%, percent of Variation Explained).Results: The association between the expression of CD23 molecule on B cells and the level of specific IgE to molecular components of mites was confirmed only in patients with dupilumab therapy. In these patiens, the highest association was confirmed between the level of specific IgE to Der p 20 and expression of CD23 on switched B lymphocytes (in 48,9 %). In patients without dupilumab, the association between the level of specific IgE to molecular components of mites and the expression of CD23 on B cells and on their subsets is low.Conclusion: Further research is needed to fully understand the underlying mechanism of this phenomenon and its implications for the treatment of atopic dermatitis.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30216 - Dermatology and venereal diseases

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical and Translational Allergy

ISSN

2045-7022

e-ISSN

2045-7022

Svazek periodika

13

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

5

Strana od-do

e12278

Kód UT WoS článku

001034663700001

EID výsledku v databázi Scopus

2-s2.0-85165557792